A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate‐Release Tablet in Healthy Adults
Clinical Pharmacology in Drug Development · 2026-06 · 15 (6)
DOI: 10.1002/cpdd.70075 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 15.06.2026. Verfasst von Michael J Hanley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, MA, USA. Hauptthemen laut MEDLINE: Pyrimidines, Organophosphorus Compounds, Protein Kinase Inhibitors. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Development Center Americas, Inc..
Abstract (Originalsprache)
Brigatinib is an ALK tyrosine kinase inhibitor approved for the treatment of adults with ALK + non‐small cell lung cancer. The commercial formulation of brigatinib is an immediate‐release (IR) tablet; however, an oral solution was developed for use in pediatric studies for patients unable to swallow solid oral dosage forms. This randomized, two‐period, two‐sequence crossover study assessed the relative bioavailability of the oral solution versus the IR tablet in healthy adults. Twelve participants received a single 90‐mg brigatinib dose as the oral solution or IR tablet on Day 1 of the first study period, followed by the alternate formulation on Day 1 of the second study period. Brigatinib pharmacokinetic parameters were similar following administration of the oral solution and IR tablet. The geometric least‐square mean ratios (oral solution vs IR tablet) for C max (0.92), AUC last (0.96), and AUC inf (0.96) were close to 1.00 with 90% confidence intervals within the bioequivalence range of 0.80–1.25 (C max , 0.87–0.98; AUC last , 0.88–1.04; AUC inf , 0.89–1.03). Treatment‐emergent adverse events were reported in three participants (25%), with the most frequent being cough (17%). These results indicate that the oral solution and IR tablet can be used interchangeably without dose adjustment in pediatric studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Förderung
- Takeda Development Center Americas, Inc.
Zitieren
APA
Hanley, M. J., Gounden, R., Hupf, B., Sarkar, S., Fram, R. J., & Gupta, N. (2026). A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate‐Release Tablet in Healthy Adults. Clinical Pharmacology in Drug Development, 15(6). https://doi.org/10.1002/cpdd.70075
Vancouver
Hanley MJ, Gounden R, Hupf B, Sarkar S, Fram RJ, Gupta N. A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate‐Release Tablet in Healthy Adults. Clinical Pharmacology in Drug Development. 2026;15(6). doi:10.1002/cpdd.70075
BibTeX
@article{Hanley2026,
author = {Hanley, Michael J and Gounden, Ronald and Hupf, Bradley and Sarkar, Saurabh and Fram, Robert J and Gupta, Neeraj},
title = {A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate‐Release Tablet in Healthy Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cpdd.70075}
}
EUVIMED